Vertex’s CRISPR therapy rebounds in latest earnings

2026-03-02 02:27:24

Vertex Pharmaceuticals saw its shares jump after reporting stronger-than-expected sales for its CRISPR gene-edited therapy, Casgevy, tripling sales from the previous quarter. The company reported $54 million in Casgevy sales for Q4 2025, contributing to its overall $12 billion in revenue for the year, and analysts are optimistic about its future sales potential for 2026. Despite challenges like the lengthy treatment process and chemotherapy side effects, patient adoption increased significantly, and Vertex anticipates smoother operations by 2027, further bolstered by potential FDA approval for younger patients and new experimental drugs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.